They now have a Dollars 42 price target on the stock. Now the stock price is moving -17.13% off from the highest level of twelve months and 8.46% above from twelve months low.
Over the past 50 days, Flexion Therapeutics, Inc. Needham & Company LLC upped their price target on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the company a "buy" rating in a report on Monday.
08/24/2017 - Northland Securities began new coverage on Flexion Therapeutics Inc giving the company a "outperform" rating. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by email at email@example.com, or by telephone at (800) 326-5897; from BMO Capital Markets Corp., 3 Times Square, 25th Floor, New York, NY 10036, Attention: Equity Syndicate Department, or by telephone at (800) 414-3627, or by email at firstname.lastname@example.org; or from RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089, or by email at email@example.com.
03/23/2017 - Flexion Therapeutics Inc had its "overweight" rating reiterated by analysts at Cantor Fitzgerald.
Analysts have given a mean recommendation of 2.80 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).
NAK's shares were trading -44.06% below from the 52-week high price mark of $3.45 and 257.41% above from the 52-week price bottom of $0.54.
Flexion Therapeutics (NASDAQ:FLXN) shares traded on 10.36% above secure line and closed at $29.93. This no-warrant financing will be the largest capital raise - at the highest price per share - in the history of 22nd Century and will raise the Company's cash balance to well over $60 million - enough to meet all regular operating expenses for more than five years.
Mitchell McClenaghan, Brendon McCullum hit by postponement of South Africa's T20 league
The SACA has called for an "independent review" because of the impact on players who turned down other opportunities to sign. Irish said other stakeholders, including franchises, coaches and stadium owners, were also affected.
Cristiano Ronaldo leads Portugal to Russian Federation and France top Group A
That set up a decisive game in Lisbon on Friday, which Portugal won 2-0. Switzerland will now enter Tuesday's draw for the play-offs. At the same time , only a defeat 7-0 to eliminate them.
Great divide between White Britons & ethnic minorities laid bare in nationwide audit
Only 54 percent of White British youngsters and 13 percent of White Gypsy and Roma children meet the same target. Only 32% of white British children who receive free school meals reach the expected Key Stage 2 standard.
Flexion Therapeutics, Inc. (FLXN)'s distance from 200 day simple moving average is 30.41 percent, its distance from 50 day simple moving average is 17.67 percent, while its distance from 20 day simple moving average is 11.84 percent. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Analysts are forecasting earnings of $-0.95 on a per share basis this quarter. "(FLXN) PT Raised to $37.00 at BMO Capital Markets" was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another domain, it was stolen and republished in violation of US and global copyright laws. The original version of this story can be viewed at https://weekherald.com/2017/10/10/janney-montgomery-scott-boosts-flexion-therapeutics-inc-flxn-price-target-to-570-00.html.
In the transaction dated Jun. 05, 2017, the great number of shares acquired came courtesy the Director, 10% Owner; Colella Samuel D added a total of 5,000 shares at an average price of $17.01, amounting to approximately $85,050. If the published price targets set by Pandora Media, Inc. analysts have any power to influence the stock's share price, the highest price target set for P is $15. Over the last three months, insiders have purchased 5,375 shares of company stock valued at $131,575. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.
It's important to get a feel for how any stock is actually valued on the market based on its core numbers. Company insiders own 15.98% of the company's stock.
Investors of this company earned a return of -38.20% on the assets it owns in past twelve month. Sei Invests Co has invested 0% in Flexion Therapeutics Inc (NASDAQ:FLXN).
In other news, insider Yamo Deniz acquired 1,375 shares of the stock in a transaction that occurred on Thursday, August 31st. Finally, American International Group Inc. lifted its stake in Flexion Therapeutics by 52.3% during the first quarter. They expect this year's earnings to fall -7.21% year-over-year to -$1.03, followed by -39.81% decline in the next year to -$0.62.
On the other hand the company has Relative Strength Index (RSI 14) of 63.14 along with Average True Range (ATR 14) of 1.78, Consequently Flexion Therapeutics (NASDAQ:FLXN)'s weekly and monthly volatility is 10.87%, 6.01% respectively. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis.